GlassScriptPhysician profile
Yee Xiong
NPI 1619247574
$1,847.76
in general payments reported to CMS, 2019-2025
14 companies · $774 in 2025
The $774 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $342 · 2022: $158 · 2023: $194 · 2024: $380 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $754.76 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $247.10 | 2021-2025 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $177.37 | 2021 | |
| Novo Nordisk INC | $139.65 | 2021-2025 | Wegovy |
| Dexcom, INC. | $121.82 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Otsuka America Pharmaceutical, INC. | $118.97 | 2023 | Rexulti |
| Corcept Therapeutics | $115.00 | 2025 | Korlym |
| Pfizer INC. | $39.84 | 2024 | |
| Novartis Pharmaceuticals Corporation | $39.63 | 2021-2022 | |
| Organon LLC | $34.78 | 2021 | |
| Medtronic, INC. | $15.62 | 2024 | Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $15.17 | 2021 | |
| Braintree Laboratories, INC. | $14.05 | 2023 | Suflave |
| Genentech USA, INC. | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yee Xiong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.